Long-term eculizumab improves clinical outcomes in atypical hemolytic uremic syndrome

Pediatric Nephrology

Volumn 27, Issue 12, 2012, Pages 2323-2326

  Vilalta, Ramon ^a   Lara, Enrique ^a   Madrid, Alvaro ^a   Chocron, Sara ^a   Muñoz, Marina ^a   Casquero, Alex ^a   Nieto, Jose ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; ECULIZUMAB; HYDRALAZINE; LABETALOL; LACTATE DEHYDROGENASE; MENINGOCOCCUS VACCINE; NIFEDIPINE; PENICILLIN DERIVATIVE; URAPIDIL; MONOCLONAL ANTIBODY;

ACUTE KIDNEY FAILURE; ANTIBIOTIC PROPHYLAXIS; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOPULMONARY INSUFFICIENCY; CASE REPORT; CHILD; CLINICAL FEATURE; CONGESTIVE CARDIOMYOPATHY; CREATININE BLOOD LEVEL; FEMALE; HEMODIALYSIS; HEMOLYTIC UREMIC SYNDROME; HUMAN; HYPERTENSION; INTUSSUSCEPTION; LACTATE DEHYDROGENASE BLOOD LEVEL; LONG TERM CARE; MENINGOCOCCEMIA; PLASMAPHERESIS; PRESCHOOL CHILD; PRIORITY JOURNAL; THROMBOTIC THROMBOCYTOPENIC PURPURA; VACCINATION; PATHOPHYSIOLOGY;

ANTIBODIES, MONOCLONAL, HUMANIZED; CHILD, PRESCHOOL; FEMALE; HEMOLYTIC-UREMIC SYNDROME; HUMANS;

EID: 84879321491     PISSN: 0931041X     EISSN: 1432198X     Source Type: Journal    
DOI: 10.1007/s00467-012-2276-8     Document Type: Article

References (9)

1. Caprioli J, Noris M, Brioschi S, Pianetti G, Castelletti F, Bettinaglio P, Mele C, Bresin E, Cassis L, Gamba S, Porrati F, Bucchioni S, Monteferrante G, Fang CJ, Liszewski MK, Kavanagh D, Atkinson JP, Remuzzi G, International Registry of Recurrent and Familial HUS/TTP (2006) Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 108:1267-1279
2. Besbas N, Karpman D, Landau D, Loirat C, Proesmans W, Remuzzi G, Rizzoni G, Taylor CM, Van de Kar N, Zimmerhackl LB, European Paediatric Research Group for HUS (2006) A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. Kidney Int 70:423-431
3. Loirat C, Frémeaux-Bacchi V (2011) Atypical hemolytic uremic syndrome. Orphanet J Rare Dis 6:60
4. Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, Daina E, Fenili C, Castelletti F, Sorosina A, Piras R, Donadelli R, Maranta R, van der Meer I, Conway EM, Zipfel PF, Goodship TH, Remuzzi G (2010) Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 5:1844-1859
5. Taylor CM, Chua C, Howie AJ, Risdon RA, British Association for Paediatric Nephrology (2004) Clinico-pathological findings in diarrhoea-negative haemolytic uraemic syndrome. Pediatr Nephrol 19:419-425
6. Zuber J, Le Quintrec M, Sberro-Soussan R, Loirat C, Frémeaux- Bacchi V, Legendre C (2011) New insights into postrenal transplant hemolytic uremic syndrome. Nat Rev Nephrol 7:23-35
7. Bianchi V, Robles R, Alberio L, Furlan M, Lammle B (2002) Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood 100:710-713
8. Châtelet V, Lobbedez T, Frémeaux-Bacchi V, Ficheux M, Ryckelynck JP, Hurault de Ligny B (2010) Eculizumab: safety and efficacy after 17 months of treatment in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome: case report. Transpl Proc 42:4353-4355
9. Rinder CS, Rinder HM, Smith BR, Fitch JC, Smith MJ, Tracey JB, Mathis LA, Squinto SP, Rollins SA (1995) Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation. J Clin Invest 96:1564-1572